Intraocular Pressure

Interpretation of OCT images by an OCT reading center may successfully reduce the number of unnecessary glaucoma specialist referrals while also maintaining a high level of quality comparable with other screening strategies.

Goldmann applanation tonometry for IOP measurement is still possible during the SARS-CoV-2 pandemic with additional steps for safety, but alternative IOP measurement devices are gaining in popularity.

Chronic hypotony is not uncommon following deep sclerectomy, but only a small proportion of patients with prolonged hypotony will develop complications that may threaten vision, according to a retrospective study.

Cataract surgery in patients treated with ocular hypotensive medications results in short-term decrease in IOP but long-term decrease in medications, Steven Mansberger, MD, MPH, said at the virtual American Glaucoma Society annual meeting.

In this video on his presentation from the virtual American Glaucoma Society meeting, Ike K. Ahmed, MD, FRCSC, discusses the 5-year data comparing the Hydrus microstent (Ivantis) combined with cataract surgery and cataract surgery alone.

The use of minimally invasive glaucoma surgery in the U.S. increased twofold, with a gradual decrease in the use of standard procedures, from 2013 to 2018, according to the IRIS Registry.

It should be the goal of every ophthalmologist to reduce the medication burden for patients with glaucoma, whether through early detection, a reliance on new devices or a combination of treatment options.

Patients with glaucoma who displayed an early treatment response to a 10 µg bimatoprost implant and experienced greater than 20% IOP lowering at 12 weeks had significantly greater odds of a long-term IOP response, according to a speaker.

As we all know, the move from intracapsular cataract surgery, where the capsule and the lens are removed together, to extracapsular, where the capsule is left in place to secure the IOL, revolutionized cataract surgery.

Patients treated with Vyzulta for open-angle glaucoma and ocular hypertension had significantly better outcomes compared with most beta-blockers, according to results of a systemic review and network meta-analysis.